Arcellx FY2024 net loss $107.3M; anito-cel Phase 2 shows 97% ORR, 62% CR/sCR

Arcellx, Inc.

2024-FY EPS reported -$2.00 revenue$107,936,000

Cash, equivalents, and marketable securities $625.7M; runway into 2027.
Collaboration revenue $107.9M in FY2024 vs $110.3M in FY2023.
Net loss $107.3M for FY2024 vs $70.7M prior year; R&D spend $157.1M.
Anito-cel pivotal iMMagine-1 data: 97% ORR, 62% CR/sCR (n=86), no delayed neurotoxicities.
Commercial launch of anito-cel in RRMM planned for 2026; iMMagine-1 update mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.